Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Achillion rides crest of hepatitis C wave

This article was originally published in Scrip

Executive Summary

Achillion could not have timed it better if it tried. A day after Merck & Co splurged $3.85bn for Idenix Pharmaceuticals' and its 'nucs' in a bid to challenge Gilead Sciences to the hepatitis C crown, comes news that the US FDA has lifted a clinical hold on Achillion's NS3/4A protease inhibitor sovaprevir. The firm has also begun dosing its nuc, ACH-3422, for seven days in patients with genotype 1 chronic hepatitis C. Proof-of-concept results from this trial are expected in the third quarter.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC025526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel